Ionis Pharmaceuticals Inc IONS

NAS: IONS | ISIN: US4622221004   6/05/2024
42,28 USD (+0,74%)
(+0,74%)   6/05/2024

25 april 2024 · Ionis Publishes 2023 Corporate Responsibility Report · Persbericht

23 april 2024 · Ionis to hold first quarter 2024 financial results webcast · Persbericht

7 april 2024 · Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome · Persbericht

1 april 2024 · Ionis to present at upcoming investor conferences · Persbericht

28 maart 2024 · Ionis to hold olezarsen Phase 3 data webcast · Persbericht

25 maart 2024 · Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting · Persbericht

13 maart 2024 · Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH · Persbericht

29 februari 2024 · Ionis announces new chief global product strategy officer to lead next phase of commercial growth · Persbericht

28 februari 2024 · Ionis to present at upcoming investor conferences · Persbericht

21 februari 2024 · Ionis reports fourth quarter and full year 2023 financial results · Persbericht

15 februari 2024 · Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome · Persbericht

8 februari 2024 · Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy · Persbericht

7 februari 2024 · Ionis to hold fourth quarter and full year 2023 financial results webcast · Persbericht

22 januari 2024 · Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema · Persbericht

8 januari 2024 · Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases · Persbericht

22 december 2023 · WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis · Persbericht

20 december 2023 · Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

18 december 2023 · Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema · Persbericht

14 december 2023 · Ionis announces the appointment of Michael Yang to Board of Directors · Persbericht

11 november 2023 · Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome · Persbericht

Mijn selecties